Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.61 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.61 |
| ▸ | F11 | P03951 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24336324 | 0.89 | LIPG (0.57) | LPLLIPGF11ESR2F2 | |
| SCHEMBL2319123 | 0.86 | LIPG (0.57) | LPLLIPGF11ESR2F2 | |
| SCHEMBL30289570 | 0.86 | LPL (0.57) | LPLLIPGF11ESR2F2 | |
| SCHEMBL28366112 | 0.84 | LIPG (0.59) | LPLLIPGF11ESR2F2 | |
| SCHEMBL2415330 | 0.84 | LPL (0.59) | LPLLIPGF11ESR2F2 | |
| SCHEMBL26983231 | 0.83 | LPL (0.54) | LPLLIPGF11ESR2F2 | |
| Ammonia Solution, Strong SCHEMBL28457989 | 0.82 | LPL (0.57) | LPLLIPGF11ESR2F2 | |
| SCHEMBL23582308 | 0.80 | F11 (0.53) | LPLLIPGF11ESR2F2 | |
| SCHEMBL15432466 | 0.80 | LPL (0.69) | LPLLIPGF11ESR2F2 | |
| SCHEMBL10006068 | 0.80 | LIPG (0.81) | LPLLIPGF11ESR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137264-A1 | POLYPHENOLIC BORONATES AND USE THEREOF | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-11576979-B2 | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof | GENENTECH, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4065230-A1 | THERAPEUTIC COMPOUNDS | Genentech, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-114835757-A | Organic electroluminescent material and device | 环球展览公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114846013-A | Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2022-08-02 | — | — | CN | disclosed |
| CN-114786778-A | Therapeutic compounds | 基因泰克公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114621294-A | Organic electroluminescent material and device | 环球展览公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2021133035-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021108483-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20190175749-A1 | PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| WO-2018031662-A1 | PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF | GENENTECH, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | LPL 111/4885LIPG 97/4885F11 1956/4885 |
| US-20190175749-A1 | PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF | NQO1, GSTP1, CYBB | LPL 4635/4885LIPG 4342/4885F11 3845/4885 |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | YAP1, YES1, TEAD2 | LPL 3536/4885LIPG 3085/4885F11 3677/4885 |
| US-11576979-B2 | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof | NQO1, GSTP1, CYBB | LPL 4635/4885LIPG 4342/4885F11 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.